Combination Therapy for First Line Treatment of Advanced Cervical Cancer
Status:
Recruiting
Trial end date:
2024-07-01
Target enrollment:
Participant gender:
Summary
This is a single center phase 1 trail to observe safety and efficacy of Paclitaxel plus
Cisplatin\Carboplatin, PD-L1 antibody Toripalimab and Anlotinib as first-line regimen to
treat the patient with metastatic 、persistent or recurrent disease after radical
surgery、radical platinum-based concurrent chemoradiotherapy or both (Stage IA-IVA).